Xenon Q4 Loss Narrower Than Expected, Pipeline Development in Focus
XENE reports a narrower-than-expected fourth-quarter 2024 loss. Its development programs for azetukalner in epilepsy and MDD ...
The Pharma Letter13h
Phase IV Ingrezza data move focus from sales outlook
Neurocrine Biosciences (Nasdaq: NBIX) has announced positive results from its Phase IV KINECT-PRO study, showing that ...